Proacta Secures $500,000 New Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    4275 Executive Square La Jolla, CA 92037
  • Company Description
    Proacta is developing a new generation of cancer drugs that uniquely target physiological attributes of solid tumors.

    Proacta’s first lead program, a hypoxia targeted small-molecule prodrug, is designed to improve the outcomes of current treatment regimens, including chemotherapy and radiotherapy. PR-104 is in Phase I clinical trials and planned to begin in a second Ph I study and a Ph II study for 2006. The second compound is planned to enter the clinic in 2007.

  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. Debt was issued in the form of convertible promissory notes. SEC regulatory filing.
  • M&A Terms
  • Venture Investor

Trending on Xconomy